Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for patients with myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). Dr. Mesa cites barriers for a racially diverse clinical trial, including patient access, financial capabilities, employment flexibility, healthcare literacy, and medical center location.

Click here to learn more.